1. Scrip
  2. >>Leadership
  3. >>Executives On The Move

Asia Executives To Watch: Betta CEO Quits To Nurture Drug Startups

 
• By Brian Yang

Betta CEO Yinxiang Wang is moving on to focus on a drug discovery incubator while another board director, Zai Lab's Samantha Du, has also resigned. Executive changes are also underway at Japanese drug startup PeptiDream.

chess

Yinxiang Wang is one of three co-founders of the Hangzhou-based Betta Pharmaceuticals Co. Ltd., along with Leiming Ding. He directly contributed to developing Betta's single and best-selling product Conmana (icotinib) for small-cell lung cancer.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Executives On The Move

Executives On The Move: Six CMOs, Five CEOs And Two CSOs Among This Week’s Changes

Recent moves in the industry include C-suite changes at Merck KGaA, Newleos Therapeutics and Artiva Biotherapeutics, plus Valo Therapeutics acquires chief executive officer from Johnson & Johnson.

Executives On The Move: Nine CEOs, Six CMOs And Three CFOs Among This Week’s Changes

Recent moves in the industry include changes at the top at Novo Nordisk and Takeda, plus Nxera Pharma nabs chief commercial officer from AstraZeneca.

Executives On The Move: Five CMOs And CCOs Each And Four CFOs Among This Week’s Changes

Recent moves in the industry include C-suite changes at 23andMe, Biomea Fusion & Alector, plus Bicycle Therapeutics acquires chief medical officer from ImmunoGen.

Executives On The Move: Harbour BioMed Gets New Chief Strategy Officer From BMS

Recent moves in the industry include C-suite changes at Cronos and Accuryn Medical, plus Dyne Therapeutics Acquires Chief Financial Officer From Editas Medicine.

More from Leadership

Biotech Leaders Fear FDA Disruption Is Causing Delays

 
• By Jessica Merrill

A letter to US Senate HELP Committee Chair Bill Cassiday sounds an alarm about irreparable damage to the FDA, signed by more than 200 biotech executives and investors.

Executives On The Move: Five CMOs And CCOs Each And Four CFOs Among This Week’s Changes

Recent moves in the industry include C-suite changes at 23andMe, Biomea Fusion & Alector, plus Bicycle Therapeutics acquires chief medical officer from ImmunoGen.

Vocal For ‘Glocal’: How Menarini Is Adapting To Outperform In The Asia Pacific

 
• By Anju Ghangurde

Menarini's Asia-Pacific CEO talks to Scrip about how the Italian group is tailoring its portfolio and pricing approach to local markets making strong strides in primary care and consumer health, while also charting a distinct path in rare diseases and oncology. The China market is also a key focus including as a potential source of innovation as is partnering, where the group has a rich history.